What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

Product Class

1289023-67-1

Product Name：Rimegepant
Molecular Formula：C28H28F2N6O3
Purity：99%
Molecular Weight：534.566

Inquiry

Product Details:

CasNo： 1289023-67-1

Molecular Formula： C28H28F2N6O3

Buy High Quality Rimegepant,Best Quality 1289023-67-1 Reasonable Price

Molecular Formula:C28H28F2N6O3
Molecular Weight:534.566
PKA:12.03±0.20(Predicted)
PSA：119.39000
Density:1.45±0.1 g/cm3(Predicted)
LogP:5.54050

Rimegepant (Cas 1289023-67-1) Usage

Description	Rimegepant is classified as a small-molecule CGRP receptor antagonist. Clinical trials have demonstrated the efficacy of rimegepant in treating acute migraine attacks, with a single dose resulting in freedom from pain and reduction in the most bothersome symptoms (such as nausea or sensitivity to light and sound) within two hours. Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. The company has continuously increased the investment on R&D facilities and state-of-the-art equipment in the past several years, including the establishment of kilogram GMP conditions plants and R&D centers. Our goal is to become a world-class leading company to support life science innovation and manufacturing.
Clinical Uses	Rimegepant, sold under the brand name Nurtec ODT, is an oral medication used for the acute treatment of migraine with or without aura in adults. It is also approved for the preventive treatment of episodic migraines. Rimegepant belongs to the class of CGRP receptor antagonists, which work by blocking the CGRP receptors involved in the pathophysiology of migraines. Rimegepant has been generally well-tolerated with a favorable safety profile. Common side effects include nausea, dizziness, upper respiratory tract infections, and sinusitis. No signs of serious liver injury or medication-overuse headaches have been detected in long-term studies.
Reactions	Rimegepant blocks calcitonin gene-related peptide (CGRP) receptors, which are thought to be involved in causing migraines. By inhibiting these receptors, rimegepant prevents the vasodilation and inflammation that contribute to migraine attacks, providing pain relief and reducing other migraine symptoms.

1289023-67-1 Relevant articles

Rimegepant oral disintegrating tablet for migraine

Lars Edvinsson

The Lancet, VOLUME 394, ISSUE 10200, P711-712, AUGUST 31, 2019

The trial was positive, showing an increase in relief from headache pain among the group receiving rimegepant at 2 h after dosing (10% over placebo) and improvement in the most bothersome symptoms, which included photophobia and nausea (8% over placebo).

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

Bixi Gao&#x;Bixi Gao † Yanbo Yang&#x;Yanbo Yang † Zilan WangZilan Wang Yue SunYue Sun Zhouqing ChenZhouqing Chen Yun ZhuYun Zhu Zhong WangZhong Wang

, Front. Pharmacol., 24 January 2020

As one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide.

Discovery of (5S,6S,9R)-5-aqmino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro- 5H-cyclohepta[b]pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): An oral Calcitonin Gene-Related Peptide (CGRP) antagonist in cinical trials for treating migraine

Luo, Guanglin,Chen, Ling,Conway, Charles M.,Denton, Rex,Keavy, Deborah,Signor, Laura,Kostich, Walter,Lentz, Kimberley A.,Santone, Kenneth S.,Schartman, Richard,Browning, Marc,Tong, Gary,Houston, John G.,Dubowchik, Gene M.,MacOr, John E.

, p. 10644 - 10651 (2013/02/23)

Calcitonin gene-related peptide (CGRP) r...

1289023-67-1 Upstream products

1190363-50-8
(5S,6S,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]-pyridin-5-ol
1289024-04-9
(5R,6S,9R)-5-chloro-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-05-0
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-06-1
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol

1289023-67-1 Downstream products

1289023-77-3
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(dimethylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
1289023-74-0
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(methylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate

Relevant Products

Pralsetinib
CAS：2097132-94-8
Etrasimod
CAS：1206123-37-6
Rivaroxaban intermediate
CAS：446292-08-6